November 28, 2016 05:21 AM ESTUpdated November 30, 06:02 AM
Bioregnum
Opinion

Juno and the FDA screwed up. Peo­ple died. What now?

Let’s say it plain and sim­ple: Juno Ther­a­peu­tics $JUNO and the FDA screwed up and pa­tients died.

The day ahead of Thanks­giv­ing, Juno man­aged to …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
ENDPOINTS CAREERS

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

TRENDING NOW

Up­dat­ed: Zealand part­ners with Roche on its amylin ana­log in a deal worth up to $5.3B

Ono li­cens­es rare blood dis­ease drug from Io­n­is for $280M up­front

Leg­end to dou­ble Carvyk­ti pro­duc­tion as it tar­gets block­buster sta­tus 

FDA’s med­ical re­view de­part­ments re­main un­touched (for now) by Musk’s cuts

Cor­rect­ed: Mer­ck opens bil­lion-dol­lar US fa­cil­i­ty to make Gar­dasil

sponsored

Obe­si­ty drug de­vel­op­ment—still room to grow

A service from the Financial Times